Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Inflammation
Published in: Inflammation 4/2010

01-08-2010

Polymorphisms in Tumor Necrosis Factor and Lymphotoxin A in Tuberculosis without and with Response to Treatment

Authors: Guadalupe García-Elorriaga, Guadalupe Carrillo-Montes, Melby Mendoza-Aguilar, César González-Bonilla

Published in: Inflammation | Issue 4/2010

Login to get access

Abstract

This study compared the frequency of the genetic polymorphisms of tumor necrosis factor (TNF) in pulmonary tuberculosis without and with response to treatment. We carried out an observational, prospective, comparative study. Three groups were studied: healthy subjects, responders, and non-responders to directly observed treatment short-course. We took a peripheral blood sample for identification of polymorphic genotypes TNF −308G/A and lymphotoxin A (LTA) +252G/A by polymerase chain reaction, and their later digestion with the Nco1 restriction enzyme. We studied a total of 138 subjects: 42 (non-responders) and 48 in each of the remaining groups. Healthy subjects had significantly high frequency of the LTA +252A allele compared to groups of patients and could be related with protection from the disease. Patients had higher frequency of the non-polymorphic allele LTA +252G than healthy subjects. With regard to LTA +252G/A genotype, we did find a significant difference with a greater frequency in the group of patients. The LTA +252G/A genotype was associated with impaired response to treatment.
Literature
1.
Mira, J.P., A. Cariou, F. Grall, C. Delclaux, M.R. Losser, F. Heshmati, et al. 1999. Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. Journal of the American Medical Association 282(6): 561–568.CrossRefPubMed
2.
Read, R.C., N.J. Camp, F.S. di Giovine, R. Borrow, E.B. Kaczmarski, A.G. Chaudhary, et al. 2000. An interleukin-1 genotype is associated with fatal outcome of meningococcal disease. Journal of Infectious Diseases 182(5): 1557–1560.CrossRefPubMed
3.
Bidwell, J., L. Keen, G. Gallagher, R. Kimberly, T. Huizinga, M.F. McDermott, et al. 1999. Cytokine gene polymorphism in human disease: on-line databases. Genes and Immunity 1(1): 3–19.CrossRefPubMed
4.
Nedwin, G.E., S.L. Naylor, A.Y. Sakaguchi, D. Smith, J. Jarrett-Nedwin, D. Pennica, et al. 1985. Human lymphotoxin and tumor necrosis factor genes: structure, homology and chromosomal localization. Nucleic Acids Research 13(17): 6361–6373.CrossRefPubMed
5.
Milner, C.N., R.C. Duncan, and J. Trowsdale. 2000. Molecular genetics of the major histocompatibility complex. In HLA in health and disease, ed. Robert Lechler and Antony Warrens, 35–50. San Diego: Academic.CrossRef
6.
Meenagh, A., F. Williams, O.A. Ross, C. Patterson, C. Gorodezky, M. Hammond, et al. 2002. Frequency of cytokine polymorphisms in populations from Western Europe, Africa, Asia, the Middle East and South America. Human Immunology 63: 1055–1061.CrossRefPubMed
7.
Roberts, A.K., F. Monzon-Bordonaba, P.G. Van Deerlin, J. Holder, G.A. Macones, M.A. Morgan, et al. 1999. Association of polymorphism within the promoter of the tumor necrosis factor alpha gene with increased risk of preterm premature rupture of the fetal membranes. American Journal of Obstetrics and Gynecology 180(5): 1297–1302.CrossRefPubMed
8.
Pociot, F., L. Briant, C.V. Jongennel, et al. 1993. Association of tumor necrosis factor (TNF) and class II major histocompatibility complex alleles with the secretion of TNF-alpha and TNF-beta by human mononuclear cells: a possible link to insulin-dependent diabetes mellitus. European Journal of Immunology 23(1): 224–231.CrossRefPubMed
9.
Keane, J. 2005. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology 44(6): 714–720.CrossRefPubMed
10.
Miller, E.A., and J.D. Ernst. 2009. Anti-TNF immunotherapy and tuberculosis reactivation: another mechanism revealed. Journal of Clinical Investigation 119(5): 1079–1082.CrossRefPubMed
11.
Delgado, J.C., A. Baena, S. Thim, and A.E. Goldfeld. 2002. Ethnic-specific genetic associations with pulmonary tuberculosis. Journal of Infectious Diseases 186(10): 1463–1468.CrossRefPubMed
12.
Goldfeld, A.E., J.C. Delgado, S. Thim, M.V. Bozon, A.M. Uglialoro, D. Turbay, et al. 1998. Association of an HLA-DQ allele with clinical tuberculosis. Journal of the American Medical Association 279(3): 226–228.CrossRefPubMed
13.
Zúñiga-Ramos, J., E. Pérez-Lina, V. Quiróz, et al. 2000. Aspectos Inmunogenéticos de la Tuberculosis Pulmonar. Revista del Instituto Nacional de Enfermedades Respiratorias, México 13(4): 240–247.
14.
Selvaraj, P., U. Sriram, K.S. Mathan, A.M. Reetha, and P.R. Narayanan. 2001. Tumour necrosis factor alpha (-238 and -308) and beta gene polymorphisms in pulmonary tuberculosis: haplotype analysis with HLA-A, B and DR genes. Tuberculosis (Edinburgh) 81(5–6): 335–341.CrossRef
15.
Pacheco, A.G., C.C. Cardoso, and M.O. Moraes. 2008. INFG +874T/A, IL-10–1082G/A and TNF -308G/A polymorphisms in association with tuberculosis susceptibility: a meta-anaysis study. Human Genetics 123(5): 477–484.CrossRefPubMed
16.
Bayley, J.P., T.H. Ottenhoff, and C.L. Verweij. 2004. Is there a future for TNF promoter polymorphisms? Genes and Immunity 5(5): 315–329.CrossRefPubMed
17.
Abraham, L.J., and K.M. Kroeger. 1999. Impact of the -308 TNF promoter plymorphism on the transcriptional regulation of the gene: relevance to disease. Journal of Leukocyte Biology 66(4): 562–566.PubMed
18.
19.
Majetschak, M., S. Flohe, U. Obertacke, J. Schroder, K. Staubach, D. Nast-Kolb, et al. 1999. Relation of a TNF gene polymorphism to severe sepsis in trauma patients. Annals of Surgery 230(2): 207–214.CrossRefPubMed
20.
Chomczynski, P. 1993. A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. Biotechniques 15(3): 532–537.PubMed
21.
Stuber, F., M. Petersen, F. Bokelmann, and U. Schade. 1996. A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis. Critical Care Medicine 24(3): 381–384.CrossRefPubMed
22.
Dell, B.R., S. Holleran, and R. Ramakrishnan. 2002. Sample size determination. ILAR Journal 43(4): 207–213.PubMed
23.
Wilson, A.G., J.A. Symons, T.L. McDowell, H.O. McDevitt, and G.W. Duff. 1997. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proceedings of the National Academy of Sciences of the United States of America 94(7): 3195–3199.CrossRefPubMed
24.
McGuire, W., A.V. Hill, C.E. Allsopp, B.M. Greenwood, and D. Kwiatkowski. 1994. Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria. Nature 371(6497): 508–510.CrossRefPubMed
25.
Al Attiyah, R., N. Madi, A.S. El Shamy, H. Wiker, P. Andersen, and A. Mustafa. 2006. Cytokine profiles in tuberculosis patients and healthy subjects in response to complex and single antigens of Mycobacterium tuberculosis. FEMS Immunology and Medical Microbiology 47(21): 254–26.PubMed
26.
Deveci, F., H.H. Akbulut, T. Turgut, and M.H. Muz. 2005. Changes in serum cytokine levels in active tuberculosis with treatment. Mediators of Inflammation 51: 256–262.CrossRef
27.
Correa, P.A., L.M. Gómez, and J.M. Anaya. 2004. Polymorphism of TNF-alpha in autoimmunity and tuberculosis. Biomedica 24(Suppl 1): 43–51.PubMed
28.
Hoffmann, S.C., E.M. Stanley, E.D. Cox, B.S. DiMercurio, D.E. Koziol, D.M. Harlan, et al. 2002. Ethnicity greatly influences cytokine gene polymorphism distribution. American Journal of Transplantation 2(6): 560–567.CrossRefPubMed
29.
Sánchez-Castillo, C.P., O. Velásquez-Monroy, A. Lara-Esqueda, A. Berber, J. Sepúlveda, R. Tapia-Conyer, et al. 2005. Diabetes and hypertension increases in a society with abdominal obesity: results of the Mexican National Health Survey 2000. Public Health Nutrition 8(1): 53–60.CrossRefPubMed
30.
Singla, R., N. Khan, N. Al-Sharif, et al. 2006. Influence of diabetes on manifestations and treatment outcome of pulmonary TB patients. International Journal of Tuberculosis and Lung Disease 10(1): 74–79.PubMed
31.
Veenstra, H., R. Baumann, N.M. Carroll, et al. 2006. Changes in leucocyte and lymphocyte subsets during tuberculosis treatmen; prominence of CD3dimCD56+ natural killer T cells in fast treatment responders. Clinical and Experimental Immunology 145(2): 252–260.CrossRefPubMed
32.
Kankova, K., I. Marova, E.H. Jansen, A. Vasku, M. Jurajda, and J. Vacha. 2002. Polymorphism Ncol in tumor necrosis factor B is associated with fasting glycemia and lipid parameters in healthy non-obese Caucasian subjects. Diabetes & Metabolism 28(3): 231–237.
33.
Laniado-Laborín, R., and N. Cabrales-Vargas. 2000. Tratamiento acortado estrictamente supervisado: estrategia necesaria pero no suficiente para controlar la tuberculosis en Baja California, México. Revista del Instituto Nacional de Enfermedades Respiratorias, México 13(1): 23–27.
34.
Frothingham, R. 2000. Mycobacteria: treatment approaches and mechanisms of resistance. Journal of Medicine Liban 48(4): 248–254.
35.
Aguillon, J.C., A. Cruzat, O. Aravena, L. Salazar, C. Llanos, and M. Cuchacovich. 2006. Could single-nucleotide polymorphisms (SNPs) affecting the tumour necrosis factor promoter be considered as part of rheumatoid arthritis evolution? Immunobiology 211(1–2): 75–84.CrossRefPubMed
36.
Szatmary, Z. 1999. Tumor necrosis factor-alpha: molecular-biological aspects minireview. Neoplasma 46(5): 257–266.PubMed
37.
Debets, J.M., R. Kampmeijer, M.P. van der Linden, W.A. Buurman, and C.J. van der Linden. 1989. Plasma tumor necrosis factor and mortality in critically ill septic patients. Critical Care Medicine 17(6): 489–494.CrossRefPubMed
38.
Gerloni, V., I. Pontikaki, M. Gattinara, et al. 2007. Biological therapy with TNF-inhibitors in pediatric rheumatology. Review of the literature and personal experience. Reumatismo 59(3): 244–261.PubMed
39.
Theis, V.S., and J.M. Rhodes. 2008. Review article: minimizing tuberculosis during anti-TNF-alpha treatment of inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 27(1): 19–30.CrossRef
Metadata
Title
Polymorphisms in Tumor Necrosis Factor and Lymphotoxin A in Tuberculosis without and with Response to Treatment
Authors
Guadalupe García-Elorriaga
Guadalupe Carrillo-Montes
Melby Mendoza-Aguilar
César González-Bonilla
Publication date
01-08-2010
Publisher
Springer US
Published in
Inflammation / Issue 4/2010
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-010-9181-8

Other articles of this Issue 4/2010

Inflammation 4/2010 Go to the issue

OriginalPaper

Carbon Nanotubes Elicit DNA Damage and Inflammatory Response Relative to Their Size and Shape

OriginalPaper

Lipid and C-Reactive Protein Levels, Cardiovascular Disease Risk Factors and Simvastatin Treatment in Brazilian Individuals

OriginalPaper

Different Mechanisms in Formation and Prevention of Indomethacin-induced Gastric Ulcers

OriginalPaper

Effects of Dexamethasone and Salvia miltiorrhizae on the Small Intestine and Immune Organs of Rats with Severe Acute Pancreatitis

OriginalPaper

Bacterial LPS Mediated Acute Inflammation-induced Spermatogenic Failure in Rats: Role of Stress Response Proteins and Mitochondrial Dysfunction

OriginalPaper

Gender-related Distribution of the Interleukin-1β and Interleukin-1 Receptor Antagonist Gene Polymorphisms in Patients with End-stage Liver Disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits